论文部分内容阅读
英国伦敦消息:3年前在国际病毒性肝炎和肝疾病讨论会上,抗病毒治疗与有希望的疗法相比,重要性居末位。今年会议有世界各地1000多名肝脏病学家和胃肠病学家参加,抗病毒疗法却大有改观。抗病毒疗法尤其是在慢性肝炎治疗中采用干扰素是一主要议题。某些研究表明,经治疗的50％或更多的病人,其病毒复制标志已消失,肝功能试验恢复正常或接近正常。但大多数病人在停止治疗后,治疗效益也终止。但研究人员却认为这种疗法显示有极优越的潜力。当前需要进一步研究,确定最适宜的剂量和治疗计划。为了维持疗效,可能需要小剂量的长期治疗。
LONDON, UNITED KINGDOM: Three years ago, antiretroviral therapy came to the fore when compared with promising therapies at the International Symposium on Viral Hepatitis and Liver Diseases. More than 1,000 hepatologists and gastroenterologists from all over the world attended this year’s conference, but antiretroviral therapy has greatly improved. Antiviral therapies, especially in the treatment of chronic hepatitis, is a major issue. Some studies have shown that in 50% or more of the treated patients, the viral replication marker has disappeared and the liver function test has returned to normal or near normal. However, most patients discontinue treatment and treatment benefits cease. But researchers think the treatment shows great potential. There is currently a need for further research to determine the most appropriate dosage and treatment plan. In order to maintain efficacy, low-dose long-term treatment may be required.